By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oxford Gene Technology today announced a licensing deal covering 12 colorectal cancer tissue biomarkers.

The exclusive license from Inven2, the technology transfer office at Oslo University Hospital, and the University of Oslo allows OGT to commercialize any test developed from the biomarkers and to sublicense the markers to other parties, OGT said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.